Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer
Ended Project Grant Awarded Last action
- Award ID
- R44CA199826
- Recipient
-
Molecular Theranostics LLC UEI L1VLYM9HZNK3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,081,265
Award facts
- Assistance listing
- 93.353 21st Century Cures Act - Beau Biden Cancer Moonshot
- Completion date
- Originally
- Funding
-
- $2,081,859.00 Federal
- -$594.00 Non-federal
- Place of performance
- Cleveland, OH 44114, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$594 | $0 | |
| Amendment | -$594 | -$594 | |
| Amendment | $0 | $0 | |
| Amendment | $81,598 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $1,450 | $0 | |
| Amendment | $999,657 | $0 | |
| Amendment | $0 | $0 | |
| Original award | $1,000,342 | $0 |
Quick answers
Who received award R44CA199826?
R44CA199826 was awarded to Molecular Theranostics LLC by National Cancer Institute (National Institutes of Health) on July 21, 2015.
How much is award R44CA199826 worth?
$2,081,265 has been obligated on R44CA199826: $2,081,859 in federal funding and -$594 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award